<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40935632</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2671-826X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Korean journal of helicobacter and upper gastrointestinal research</Title><ISOAbbreviation>Korean J Helicobacter Up Gastrointest Res</ISOAbbreviation></Journal><ArticleTitle>Therapeutic Potential of Melatonin in Functional Dyspepsia.</ArticleTitle><Pagination><StartPage>296</StartPage><EndPage>298</EndPage><MedlinePgn>296-298</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7704/kjhugr.2025.0037</ELocationID><Abstract><AbstractText>Melatonin has demonstrated potential therapeutic benefits across a range of functional gastrointestinal disorders, including irritable bowel syndrome and heartburn, due to its effects on motility regulation, visceral sensitivity, and gut-brain signaling. To assess its efficacy specifically in functional dyspepsia (FD), we conducted a meta-analysis of three randomized controlled trials (RCTs) involving a total of 148 patients (74 in each of the melatonin and placebo groups). The primary outcome was symptom improvement following melatonin supplementation. The fixed-effect model revealed a statistically significant benefit (odds ratio [OR], 4.96; 95% confidence interval [CI], 2.19-11.27; p&lt;0.001), whereas the random-effects model showed a non-significant trend toward improvement (OR, 4.59; 95% CI, 0.82-25.80). These findings indicate that melatonin may be a promising adjunctive treatment for FD. However, the small number of RCTs and the age of the included studies limit definitive conclusions; large&#x2011;scale, recent trials are needed to define the optimal target population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeon Ji</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><MedlineTA>Korean J Helicobacter Up Gastrointest Res</MedlineTA><NlmUniqueID>101258142</NlmUniqueID><ISSNLinking>1738-3331</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dyspepsia</Keyword><Keyword MajorTopicYN="N">Gastrointestinal diseases</Keyword><Keyword MajorTopicYN="N">Melatonin</Keyword></KeywordList><CoiStatement>
<b>Conflicts of Interest</b>
. Yeon Ji Kim, a contributing editor of the <i>Korean Journal of Helicobacter and Upper Gastrointestinal Research</i>, was not involved in the editorial evaluation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>21</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40935632</ArticleId><ArticleId IdType="pmc">PMC12425662</ArticleId><ArticleId IdType="doi">10.7704/kjhugr.2025.0037</ArticleId><ArticleId IdType="pii">kjhugr.2025.0037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lynch HJ, Ozaki Y, Wurtman RJ. The measurement of melatonin in mammalian tissues and body fluids. J Neural Transm Suppl. 1978:251&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">288852</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan V, Smits M, Spence W, et al. Melatonin in mood disorders. World J Biol Psychiatry. 2006;7:138&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861139</ArticleId></ArticleIdList></Reference><Reference><Citation>Palagini L, Manni R, Aguglia E, et al. International expert opinions and recommendations on the use of melatonin in the treatment of insomnia and circadian sleep disturbances in adult neuropsychiatric disorders. Front Psychiatry. 2021;12:688890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222620</ArticleId><ArticleId IdType="pubmed">34177671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonon AC, Pilz LK, Markus RP, Hidalgo MP, Elisabetsky E. Melatonin and depression: a translational perspective from animal models to clinical studies. Front Psychiatry. 2021;12:638981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060443</ArticleId><ArticleId IdType="pubmed">33897495</ArticleId></ArticleIdList></Reference><Reference><Citation>Geoffroy PA, Etain B, Franchi JA, Bellivier F, Ritter P. Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders. Curr Pharm Des. 2015;21:3352&#x2013;3358.</Citation><ArticleIdList><ArticleId IdType="pubmed">26088111</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KH, Zeng BY, Zeng BS, et al. The efficacy of exogenous melatonin supplement in ameliorating irritable bowel syndrome severity: a meta-analysis of randomized controlled trials. J Formos Med Assoc. 2023;122:276&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">36257872</ArticleId></ArticleIdList></Reference><Reference><Citation>Faghih Dinevari M, Jafarzadeh F, Jabbaripour Sarmadian A, Abbasian S, Nikniaz Z, Riazi A. The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study. BMC Gastroenterol. 2023;23:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10131443</ArticleId><ArticleId IdType="pubmed">37098505</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu PP, Hempole H, Krishnaswamy N, Shah NJ, Aloysius M. The effect of melatonin in functional heartburn: a randomized, placebo-controlled clinical trial. Open J Gastroenterol. 2014;4:56&#x2013;61.</Citation></Reference><Reference><Citation>Klupi&#x144;ska G, Poplawski T, Drzewoski J, et al. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol. 2007;41:270&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">17426465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zybach K, Friesen CA, Schurman JV. Therapeutic effect of melatonin on pediatric functional dyspepsia: a pilot study. World J Gastrointest Pharmacol Ther. 2016;7:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4734949</ArticleId><ArticleId IdType="pubmed">26855822</ArticleId></ArticleIdList></Reference><Reference><Citation>Chojnacki C, M&#x119;drek-Socha M, Konrad P, Chojnacki J, B&#x142;o&#x144;ska A. The value of melatonin supplementation in postmenopausal women with Helicobacter pylori-associated dyspepsia. BMC Womens Health. 2020;20:262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691069</ArticleId><ArticleId IdType="pubmed">33243209</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>